Mapi Pharma again considers Nasdaq IPO

Nasdaq
Nasdaq

Mapi will now raise $10-30 million in the first quarter of 2015, either through an IPO or a private placement.

Mapi Pharma, which develops delayed release drugs, including a delayed release version of Teva Pharmaceutical Industries Ltd.'s (NYSE: TEVA; TASE: TEVA) Copaxone, has begun a trial of this product's effectiveness on humans, and is again considering an IPO. Founded by former Teva employees, Mapi is managed by CEO Ehud Marom. Its version of Copaxone is designed to release the drug only once a month, instead of once every two days in the less frequent version currently offered by Teva.

Mapi attempted an IPO on Nasdaq in the second half of 2014, seeking to raise $40 million at a company value of $200-230 million. When the company was unable to raise this amount, it cut the amount to be raised to $20 million at a $120 million company value, but was still unable to complete the offering, and postponed its efforts to a later date.

Marom says that Mapi will now raise $10-30 million in the first quarter of 2015, either through an offering to the public or a private placement. Another option is giving the commercial rights to the drug to a corporation operating in the multiple sclerosis field. Marom does not deny that Teva itself is interested in the product.

Marom believes that Mapi is currently well positioned for an offering, because the Copaxone segment in which it is seeking to operate now appears more secure, while imitating or devising a substitute for Copaxone is proving more difficult than previously thought.

"When we enter the market in 2018, we'll probably be competing in a Copaxone market of $1 billion or more, not just several hundred million dollars, as we thought in our attempted IPO," Marom said.

Meanwhile, Mapi has signed three more agreements with other companies for joint development of delayed release generic drugs. According to Marom, the first product from these ventures is scheduled to reach the market in 2017.

Because it uses a recognized molecule, Mapi needs to submit to the US Food and Drug Administration (FDA) only the result of its Phase III trial, but it has decided to conduct a Phase II trial, both in order to learn about the patients' response before entering the critical trial and to obtain earlier effectiveness results. Marom estimates that $30 million will be enough to finance both trials.

Published by Globes [online], Israel business news - www.globes-online.com - on December 23, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

Inflation  credit: Tali Bogdanovsky Unexpectedly low February CPI reading cuts inflation

While inflation in Israel in the 12 months to the end of February 2025 is lower than forecast, housing prices continue to rise.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Competition Authority allows Delek takeover of Isracard

The Competition Authority is considered the easier of the two regulatory hurdles that the deal must overcome, the other being the Supervisor of Banks.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

Gabi Seroussi illustration: Gil Gibli Board chooses Seroussi as IAI chair as Erdan freezes candidacy

Israel Aerospace Industries board chose Gabi Seroussi as chair even though he did not to go through the preliminary process of the Government Companies Authority appointments review committee.

Bavli Park penthouse credit: Eyal Tagar Tel Aviv Park Bavli penthouse sells for NIS 43m

A 44th floor penthouse in one of the two towers in businessman Yitzhak Tshuva's Park Bavli project has been bought by an Israeli businessperson.

El Al aircraft  credit: Yoav Yaari El Al pilots receive nearly NIS 250,000 bonus each

Thanks to the agreements signed with the unions in 2018, El Al's employees as well as senior management share in last year's success.

Pentera CEO Amitai Ratzon credit: Eyal Izhar Israeli security validation co Pentera raises $60m

Pentera's platform enables security teams to analyze complete attack paths, identify root causes, and prioritize remediation for effective risk reduction.

Tel Aviv credit: Shutterstock Supply of unsold new homes hits record

Israel's real estate market is sliding into recession with 78,000 unsold new apartments in January, the Central Bureau of Statistics reports.

D&B chairman Doron Cohen and Meitar partner Dan Geva Meitar reclaims title of Israel's biggest law firm

Meitar has first place with 537 lawyers, followed by Herzog Fox Neeman with 512 lawyers, according to the latest Dun's 100 rankings.

First International Bank of Israel CEO Eli Cohen  credit: Eyal Toueg First Int'l posts top return on equity

First International Bank of Israel's return on equity in 2024 was 19%, the highest among Israel's banks.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al almost quintuples profit

The airline posted a net profit of $545 million for 2024, 4.7 times the profit in 2023, and an all-time high.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018